Nexavar in combination with carboplatin and paclitaxel is contraindicated in patients with squamous cell lung cancer. Cardiac ischemia and/or myocardial infarction may occur. Temporary or permanent discontinuation of Nexavar should be considered in patients who develop cardiac ischemia and/or myocardial infarction. An increased risk of bleeding may occur following Nexavar administration. If bleeding necessitates medical intervention, consider permanent discontinuation of Nexavar. continue reading below »
The goal of therapy for unresectable HCC remains the same: to extend survival.1 Nexavar has been proven to extend overall survival in patients with unresectable HCC in randomized, placebo-controlled trials.1
To help deliver benefit to patients who may need it most, surveillance is important for improving diagnosis and HCC treatment rates.
Click through for more information about the following topics and how Nexavar can fit seamlessly into your treatment plan:
Reference: 1. Bruix J, Sherman M. Management of Hepatocellular Carcinoma: An Update. Alexandria, VA: American Association for the Study of Liver Diseases.
NCCN=National Comprehensive Cancer Network; BCLC=Barcelona Clinic Liver Cancer.